Elemer Piros
Stock Analyst at Rodman & Renshaw
(2.90)
# 1,232
Out of 4,479 analysts
92
Total ratings
35.79%
Success rate
0.09%
Average return
Main Sectors:
30 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ANVS Annovis Bio | Reiterates: Buy | $67 | $9.16 | +631.44% | 1 | Jul 2, 2024 | |
| ANRO Alto Neuroscience | Initiates: Buy | $43 | $11.52 | +273.43% | 1 | Jun 21, 2024 | |
| COYA Coya Therapeutics | Initiates: Buy | $18 | $6.13 | +193.64% | 7 | Jun 13, 2024 | |
| HOTH Hoth Therapeutics | Maintains: Buy | $12 → $7.5 | $0.91 | +724.18% | 3 | Sep 14, 2023 | |
| ATAI Atai Life Sciences | Reiterates: Buy | $15 | $1.31 | +1,045.04% | 8 | Aug 9, 2023 | |
| MNMD Mind Medicine (MindMed) | Reiterates: Buy | $21 | $7.00 | +200.00% | 8 | Aug 4, 2023 | |
| CMPS COMPASS Pathways | Reiterates: Buy | $38 | $5.92 | +541.89% | 9 | Aug 3, 2023 | |
| KTTA Pasithea Therapeutics | Reiterates: Buy | $40 | $4.83 | +728.16% | 2 | Jul 10, 2023 | |
| UNCY Unicycive Therapeutics | Reiterates: Buy | $5 | $0.49 | +930.72% | 5 | Jun 30, 2023 | |
| CYBN Cybin | Reiterates: Buy | $3 | $0.26 | +1,071.88% | 3 | Jun 20, 2023 | |
| CLNN Clene | Maintains: Buy | $13 → $10 | $0.32 | +3,025.00% | 6 | Jun 20, 2023 | |
| OPT Opthea | Reiterates: Buy | $23 | $1.96 | +1,073.47% | 2 | May 16, 2023 | |
| MNPR Monopar Therapeutics | Maintains: Buy | $24 → $17 | $0.73 | +2,229.72% | 5 | Mar 28, 2023 | |
| GHRS GH Research | Reiterates: Buy | $33 | $11.86 | +178.36% | 3 | Mar 2, 2023 | |
| APLS Apellis Pharmaceuticals | Downgrades: Sell | $40 | $35.59 | +12.39% | 6 | Apr 14, 2022 | |
| UBX Unity Biotechnology | Upgrades: Buy | $40 | $1.31 | +2,953.44% | 3 | Jan 4, 2022 | |
| BRTX BioRestorative Therapies | Initiates: Buy | n/a | $1.93 | - | 1 | Dec 1, 2021 | |
| DMAC DiaMedica Therapeutics | Maintains: Buy | n/a | $2.80 | - | 2 | Jun 30, 2021 | |
| DRRX DURECT | Initiates: Buy | n/a | $1.34 | - | 1 | Oct 12, 2020 | |
| CWBR CohBar | Initiates: Buy | n/a | $0.51 | - | 1 | Sep 17, 2020 | |
| CRBP Corbus Pharmaceuticals Holdings | Downgrades: Neutral | n/a | $48.17 | - | 3 | Sep 8, 2020 | |
| ARCT Arcturus Therapeutics Holdings | Reinstates: Buy | n/a | $21.16 | - | 1 | Jul 30, 2020 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Overweight | n/a | $25.04 | - | 3 | Dec 17, 2018 | |
| KRYS Krystal Biotech | Initiates: Overweight | n/a | $179.30 | - | 1 | Sep 11, 2018 | |
| COOL Corner Growth Acquisition | Maintains: Overweight | n/a | $11.10 | - | 1 | Jun 13, 2018 | |
| DVAX Dynavax Technologies | Maintains: Overweight | n/a | $11.08 | - | 2 | Nov 10, 2017 | |
| ALDX Aldeyra Therapeutics | Initiates: Overweight | n/a | $3.18 | - | 1 | Oct 25, 2017 | |
| ABEO Abeona Therapeutics | Maintains: Overweight | n/a | $4.14 | - | 1 | Oct 12, 2017 | |
| OCUL Ocular Therapeutix | Maintains: Overweight | n/a | $6.59 | - | 1 | Jul 12, 2017 | |
| OMER Omeros | Downgrades: Neutral | n/a | $3.86 | - | 1 | May 11, 2017 |
Annovis Bio
Jul 2, 2024
Reiterates: Buy
Price Target: $67
Current: $9.16
Upside: +631.44%
Alto Neuroscience
Jun 21, 2024
Initiates: Buy
Price Target: $43
Current: $11.52
Upside: +273.43%
Coya Therapeutics
Jun 13, 2024
Initiates: Buy
Price Target: $18
Current: $6.13
Upside: +193.64%
Hoth Therapeutics
Sep 14, 2023
Maintains: Buy
Price Target: $12 → $7.5
Current: $0.91
Upside: +724.18%
Atai Life Sciences
Aug 9, 2023
Reiterates: Buy
Price Target: $15
Current: $1.31
Upside: +1,045.04%
Mind Medicine (MindMed)
Aug 4, 2023
Reiterates: Buy
Price Target: $21
Current: $7.00
Upside: +200.00%
COMPASS Pathways
Aug 3, 2023
Reiterates: Buy
Price Target: $38
Current: $5.92
Upside: +541.89%
Pasithea Therapeutics
Jul 10, 2023
Reiterates: Buy
Price Target: $40
Current: $4.83
Upside: +728.16%
Unicycive Therapeutics
Jun 30, 2023
Reiterates: Buy
Price Target: $5
Current: $0.49
Upside: +930.72%
Cybin
Jun 20, 2023
Reiterates: Buy
Price Target: $3
Current: $0.26
Upside: +1,071.88%
Clene
Jun 20, 2023
Maintains: Buy
Price Target: $13 → $10
Current: $0.32
Upside: +3,025.00%
Opthea
May 16, 2023
Reiterates: Buy
Price Target: $23
Current: $1.96
Upside: +1,073.47%
Monopar Therapeutics
Mar 28, 2023
Maintains: Buy
Price Target: $24 → $17
Current: $0.73
Upside: +2,229.72%
GH Research
Mar 2, 2023
Reiterates: Buy
Price Target: $33
Current: $11.86
Upside: +178.36%
Apellis Pharmaceuticals
Apr 14, 2022
Downgrades: Sell
Price Target: $40
Current: $35.59
Upside: +12.39%
Unity Biotechnology
Jan 4, 2022
Upgrades: Buy
Price Target: $40
Current: $1.31
Upside: +2,953.44%
BioRestorative Therapies
Dec 1, 2021
Initiates: Buy
Price Target: n/a
Current: $1.93
Upside: -
DiaMedica Therapeutics
Jun 30, 2021
Maintains: Buy
Price Target: n/a
Current: $2.80
Upside: -
DURECT
Oct 12, 2020
Initiates: Buy
Price Target: n/a
Current: $1.34
Upside: -
CohBar
Sep 17, 2020
Initiates: Buy
Price Target: n/a
Current: $0.51
Upside: -
Corbus Pharmaceuticals Holdings
Sep 8, 2020
Downgrades: Neutral
Price Target: n/a
Current: $48.17
Upside: -
Arcturus Therapeutics Holdings
Jul 30, 2020
Reinstates: Buy
Price Target: n/a
Current: $21.16
Upside: -
Arrowhead Pharmaceuticals
Dec 17, 2018
Maintains: Overweight
Price Target: n/a
Current: $25.04
Upside: -
Krystal Biotech
Sep 11, 2018
Initiates: Overweight
Price Target: n/a
Current: $179.30
Upside: -
Corner Growth Acquisition
Jun 13, 2018
Maintains: Overweight
Price Target: n/a
Current: $11.10
Upside: -
Dynavax Technologies
Nov 10, 2017
Maintains: Overweight
Price Target: n/a
Current: $11.08
Upside: -
Aldeyra Therapeutics
Oct 25, 2017
Initiates: Overweight
Price Target: n/a
Current: $3.18
Upside: -
Abeona Therapeutics
Oct 12, 2017
Maintains: Overweight
Price Target: n/a
Current: $4.14
Upside: -
Ocular Therapeutix
Jul 12, 2017
Maintains: Overweight
Price Target: n/a
Current: $6.59
Upside: -
Omeros
May 11, 2017
Downgrades: Neutral
Price Target: n/a
Current: $3.86
Upside: -